



Contents lists available at ScienceDirect

Brain Behavior and Immunity

journal homepage: www.elsevier.com/locate/ybrbi

Corrigendum



Corrigendum to “COVID-19 vaccination for the prevention and treatment of long COVID: A systematic review and meta-analysis” [Brain Behav. Immun. 111 (2023) 211–229]

Felicia Ceban^{a,b,c}, Dana Kulzhabayeva^d, Nelson B. Rodrigues^a, Joshua D. Di Vincenzo^a, Hartej Gill^{a,j}, Mehala Subramaniapillai^{a,c}, Leanna M.W. Lui^{a,j}, Bing Caoⁱ, Rodrigo B. Mansur^{a,e}, Roger C. Ho^{g,h}, Matthew J. Burke^{e,k,l}, Taeho Greg Rhee^{m,n}, Joshua D. Rosenblat^{a,e}, Roger S. McIntyre^{a,c,e,f,j,*}

^a Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, Ontario, Canada

^b Michael G. DeGroot School of Medicine, McMaster University, Hamilton, Ontario, Canada

^c Brain and Cognition Discovery Foundation, Toronto, Ontario, Canada

^d Department of Psychology, University of Toronto, Toronto, Ontario, Canada

^e Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada

^f Department of Pharmacology and Toxicology, University of Toronto, Toronto, Ontario, Canada

^g Department of Psychological Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 119228, Singapore

^h Institute for Health Innovation and Technology (iHealthtech), National University of Singapore, Singapore 119077, Singapore

ⁱ Key Laboratory of Cognition and Personality, Faculty of Psychology, Ministry of Education, Southwest University, Chongqing 400715, China

^j Institute of Medical Science, University of Toronto, Toronto, Ontario, Canada

^k Hurvitz Brain Sciences Program, Sunnybrook Research Institute, Toronto, Canada

^l Department of Neurology, Division of Cognitive Neurology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA

^m Department of Psychiatry, Yale School of Medicine, New Haven, CT, USA

ⁿ Department of Public Health Sciences, University of Connecticut School of Medicine, Farmington, CT, USA

The authors regret that “Bharat Biotech Covaxin” was misreported as “Novavax-Serum Institute Covovax NVX-CoV2373”. The locations of the error in the manuscript are:

- Page 214, paragraph 1, sentence 4
- Page 214, Section 3.4.1. SARS-CoV-2 vaccination for the prevention of long COVID, paragraph 1, sentence 2
- Page 214, section 3.4.1. SARS-CoV-2 vaccination for the prevention of long COVID, paragraph 5, sentence 1
- Table 1, Page 216, Row: “Arjun et al, 2022*”, Column: “Vaccinated (Treatment) Group”, last bullet point

At the foregoing locations in the text, “Novavax-Serum Institute

Covovax NVX-CoV2373” should read “Bharat Biotech Covaxin”. Notably, one of the component studies reported that two doses of the Bharat Biotech Covaxin vaccine were associated with an increased odds of long COVID (aOR 2.32, 95% CI 1.17–4.58, $p = 0.01$, $N = 487$)¹; this finding was not reported in association with the Novavax-Serum Institute Covovax NVX-CoV2373 vaccine. The authors would like to apologize for any inconvenience caused.

1. Arjun MC, Singh AK, Pal D, et al. Prevalence, characteristics, and predictors of Long COVID among diagnosed cases of COVID-19. *bioRxiv*. Published online January 8, 2022. <https://doi.org/10.1101/2022.01.04.21268536>.

DOI of original article: <https://doi.org/10.1016/j.bbi.2023.03.022>.

* Corresponding author at: Suite 600, 77 Bloor St W, Toronto, ON M5S 1M2, Canada.

E-mail address: Roger.mcintyre@bcdf.org (R.S. McIntyre).

<https://doi.org/10.1016/j.bbi.2023.09.020>